×

Sign In

Search
Home

Zealand Pharma to start phase 2b trial for obesity drug candidate in Q4

By Thomson Reuters Nov 7, 2024 | 12:20 AM

COPENHAGEN (Reuters) – Danish biotechnology company Zealand Pharma said on Thursday it expected to initiate a phase 2b trial with its obesity treatment candidate petrelintide in the fourth quarter of 2024.

(Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)

Vatican's chief diplomat congratulates Trump, wishes him 'great wisdom'

North Korea-Russia ties are also a threat to US security, NATO chief says

Turkey expects lower U.S. tariffs under Trump, lira rallies

Spain floods: Improvised vet station treats pets sick from tainted mud

New UK sanctions on Russia also target Africa Corps

Biden set to address nation after Trump's decisive U.S. election win

Privacy Policy
Terms Of Service

Midwest Communications, Inc.

Copyright © 2024. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.